News Breaks |
|
|
| December 14, 2012 |
| 07:31 EDT |  | ISIS, SNY | Genzyme, Isis say CHMP adopts negative opinion on KYNAMRO MAA
Genzyme, a Sanofi company (SNY), and Isis Pharmaceuticals (ISIS), announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMRO for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion. An application for KYNAMRO is currently under review by the U.S. Food and Drug Administration. In October, KYNAMRO received a positive vote by an FDA advisory panel that Genzyme had provided sufficient efficacy and safety data to support the marketing of KYNAMRO for the treatment of patients with Homozygous Familial Hypercholesterolaemia. |
|
|
News For SNY;ISIS From The Last 14 Days Check below for free stories on SNY;ISIS the last two weeks. |
|
|
| May 17, 2013 |
| 08:03 EDT | | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
 Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 15, 2013 |
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
|
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT |  | SNY | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:30 EDT |  | SNY | TechConnect to host a summit
2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. |
|
| May 10, 2013 |
| 11:48 EDT | | SNY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| May 9, 2013 |
| 16:59 EDT | | ISIS | Isis Pharmaceuticals earns $3.5M from Biogen
Subscribe for More Information |
|
| 11:15 EDT |  | ISIS | High option volume stocks: BKS ISIS BRY GMCR JOE
|
|
| 06:16 EDT |  | ISIS | Isis Pharmaceuticals 9M share Secondary priced at $19.00
Subscribe for More Information |
| |
| May 7, 2013 |
| 16:35 EDT |  | ISIS | Isis Pharmaceuticals reports Q1 EPS (2c), consensus (2c)
Subscribe for More Information |
|
| 16:05 EDT | | ISIS | Isis Pharmaceuticals files to sell common stock, no amount given
|
|
| May 6, 2013 |
| 07:49 EDT | | SNY | Bernstein's global pharmaceuticals analyst has analyst/industry conference call
Subscribe for More Information |
|
| 07:05 EDT | | ISIS | Isis Pharmaceuticals announces initiation of a clinical study of ISIS-STAT3 Rx
Subscribe for More Information |
|
|
|
|
|
